2021
Intraindividual pain variability and phenotypes of pain in sickle cell disease: a secondary analysis from the Pain in Sickle Cell Epidemiology Study
Bakshi N, Gillespie S, McClish D, McCracken C, Smith W, Krishnamurti L. Intraindividual pain variability and phenotypes of pain in sickle cell disease: a secondary analysis from the Pain in Sickle Cell Epidemiology Study. Pain 2021, 163: 1102-1113. PMID: 34538841, PMCID: PMC9100443, DOI: 10.1097/j.pain.0000000000002479.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidAnemia, Sickle CellHumansOpioid-Related DisordersPainPhenotypeQuality of LifeConceptsSickle cell diseaseSickle Cell Epidemiology StudyOpioid useMean painPain variabilityPhysical functionPain intensityPain phenotypesPatient outcomesCell diseaseEpidemiology studiesHigher mean painLower mean painLow physical functionHealth-related qualityHealth care utilizationHigher physical functionProportion of daysSomatic symptom burdenSymptom burdenCare utilizationPainSecondary analysisSpearman rank correlationHigh temporal instability
2019
Management of Chronic Pain in Adults Living With Sickle Cell Disease in the Era of the Opioid Epidemic
Sinha C, Bakshi N, Ross D, Krishnamurti L. Management of Chronic Pain in Adults Living With Sickle Cell Disease in the Era of the Opioid Epidemic. JAMA Network Open 2019, 2: e194410. PMID: 31125105, PMCID: PMC6632133, DOI: 10.1001/jamanetworkopen.2019.4410.Peer-Reviewed Original ResearchConceptsSickle cell diseaseOpioid epidemicOpioid usePain managementChronic painAlternative therapiesCell diseaseAfrican American race/ethnicityDisease controlVaso-occlusive painPain medication useChronic pain managementSickle cell clinicCurrent opioid epidemicRace/ethnicityOpioid dosingOpioid dosageOpioid prescriptionsAdult patientsMedian ageMedication usePersistent painComprehensive careMAIN OUTCOMEPain
2015
A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children
Brousseau D, Scott J, Badaki-Makun O, Darbari D, Chumpitazi C, Airewele G, Ellison A, Smith-Whitley K, Mahajan P, Sarnaik S, Casper T, Cook L, Dean J, Leonard J, Hulbert M, Powell E, Liem R, Hickey R, Krishnamurti L, Hillery C, Nimmer M, Panepinto J, Network F. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood 2015, 126: 1651-1657. PMID: 26232172, PMCID: PMC4591790, DOI: 10.1182/blood-2015-05-647107.Peer-Reviewed Original ResearchConceptsSickle cell pain crisisLength of stayPediatric Emergency Care Applied Research NetworkPain crisisIntravenous magnesiumOpioid useNormal saline placeboStudy drug infusionPlacebo-controlled trialHealth-related qualityQuality of lifeMorphine equivalentsStudy drugSaline placeboSecondary outcomesStandard therapyHemoglobin SSPediatric patientsPrimary outcomeDrug infusionPain relieversPlaceboStayChildren 4Group demographicsRandomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use
Telen M, Wun T, McCavit T, De Castro L, Krishnamurti L, Lanzkron S, Hsu L, Smith W, Rhee S, Magnani J, Thackray H. Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood 2015, 125: 2656-2664. PMID: 25733584, PMCID: PMC4408290, DOI: 10.1182/blood-2014-06-583351.Peer-Reviewed Original ResearchConceptsVaso-occlusive crisisSickle cell diseaseComposite primary end pointPrimary end pointPhase 2 studyEnd pointRandomized phase 2 studySCD vaso-occlusive crisisOpioid analgesic useSecondary end pointsActive treatment groupPhase 3 studyVaso-occlusive eventsAnalgesic usePlacebo groupProspective multicenterStudy drugAdverse eventsOpioid useSymptom reliefMedian timeSCD patientsCell diseaseTreatment groupsAnimal models